Compare Eos Energy Enterprises Inc (EOSE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Mesoblast Limited — how do they compare? Eos Energy Enterprises Inc trades at $2.66 (market cap $1.01B), while Mesoblast Limited trades at $14.18 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Mesoblast Limited for 14 Days on average.
| EOSE | MESO | |
|---|---|---|
Market Cap | $1.01B | $1.75B |
Volume | 39,626,541 | 239,027 |
Sector | Industrials | Health |
52-Week High | $19.19 | $20.96 |
52-Week Low | $2.77 | $13.19 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $1.34B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.645, down 14.68% in the last session, reflecting significant volatility amid mixed quarterly results. The company shows rapid revenue growth but deep losses, with a -246.76% net income margin in 2026. Recent developments include a $87 million DOE loan advance and a partnership with Google for a West Virginia energy project, highlighting growth potential in long-duration energy storage.
The outlook is bifurcated: strong revenue growth and strategic partnerships offer upside, but persistent losses and high debt-to-asset ratio of 91.87% pose substantial risks. Analyst consensus is cautious with a $7.10 price target, suggesting 168% potential upside, yet the bearish technical signal and negative cash flows from operations warrant careful monitoring of execution and funding needs.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
